• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Better Benefits, Fewer Risks

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-05-01-2001
Volume 0
Issue 0

Straddling the divide between drug discovery and drug delivery, Protarga doesn't fit neatly into any pharma category. It's not exactly a delivery technology company, because its products are patentable new entities that it plans to keep for itself. Nor is it purely biotech, because it works with chemical compounds. And in the end, president and CEO Nigel Webb expects Protarga to become a fully integrated pharma company-but only in the virtual sense.

Related Videos
Related Content